

Weekly

July 15, 2005 / Vol. 54 / No. 27

Update: Syringe Exchange Programs — United States, 2002

Syringe exchange programs (SEPs) provide sterile syringes* in exchange for used syringes to reduce transmission of human immunodeficiency virus (HIV) and other bloodborne infections associated with reuse of contaminated syringes by injection-drug users (IDUs) (1). This report summarizes a survey of SEP activities in the United States for January-December 2002 and compares the results with those of previous surveys. The findings indicate that in 2002, for the first time in 8 years, the number of SEPs, the number of localities with SEPs, and public funding for SEPs decreased nationwide; however, the number of syringes exchanged and total budgets across all programs continued to increase. SEPs can help prevent bloodborne pathogen transmission by increasing access to sterile syringes among IDUs and enabling safe disposal of used syringes. Often, programs also provide other public health services, such as HIV testing, riskreduction education, and referrals for substance-abuse treatment.

In December 2002, staff from Beth Israel Medical Center (BIMC) in New York City and the North American Syringe Exchange Network (NASEN) mailed surveys about syringes exchanged and returned, services provided, and budgets and funding to the directors of all 148 SEPs known to NASEN (compared with 154 known SEPs for the 2000 survey, 131 for 1998, 113 for 1997, 101 for 1996, and 68 for 1994–95) (2–5; BIMC, unpublished data, 2000). Data for 2002 were collected from SEP directors during January–July 2003 through telephone interviews with BIMC staff, Internet-based questionnaires, or paper questionnaires returned by fax or mail. With the exception of the Internet-based option, the methods were similar to those used for previous surveys (2–5).

Of 148 SEP directors contacted, 126 (85%) completed the survey. These 126 SEPs reported operating in 102 cities[†] in

31 states and the District of Columbia (DC).[§] More than two-thirds (86) of SEPs were in seven states: California (25), Washington (15), New Mexico (14), New York (12), Wisconsin (eight), Massachusetts (six), and Oregon (six).

SEP size was classified by the number of syringes exchanged (Table 1); 119 SEPs reported exchanging a total of 24,878,033 syringes; seven SEPs did not track the number of syringes exchanged. The 11 largest programs[¶] exchanged 49% of all syringes.

SEPs provided other services in addition to syringe exchange. One hundred ten (87%) SEPs provided male condoms, 96 (76%) female condoms, 111 (88%) alcohol pads, and 86 (68%) bleach; 97 (77%) provided referrals for substance-abuse

INSIDE

- 678 West Nile Virus Activity United States, 2005
- 679 Notices to Readers
- 680 QuickStats

^{*} For this report, the term "syringes" refers to both syringes and needles.

[†] Cities with more than one SEP: Albuquerque, New Mexico; Chicago, Illinois; Los Angeles, California; Madison, Wisconsin; New York, New York; Portland, Oregon; San Francisco, California; Seattle, Washington; and Tacoma, Washington.

[§] States with SEPs: California (25); Washington (15); New Mexico (14); New York (12); Wisconsin (eight); Oregon and Massachusetts (six each); Connecticut and Illinois (five each); Michigan (three); Minnesota, North Carolina, Pennsylvania, Texas, and Vermont (two each); Alaska, Arizona, Colorado, DC, Georgia, Hawaii, Indiana, Kansas, Louisiana, Maine, Missouri, New Jersey, Ohio, Oklahoma, Rhode Island, Tennessee, and Utah (one each).

⁹ Largest volume SEPs: Chicago Recovery Alliance (2.7 million syringes), Chicago, Illinois; San Francisco AIDS Foundation HIV Prevention Project (2.5 million), San Francisco, California; Seattle-King County Department of Public Health Needle Exchange Program, Seattle, Washington (1.0 million); Harm Reduction Institute, Indianapolis, Indiana (1.0 million); Point Defiance AIDS Project, Tacoma, Washington (0.9 million); San Diego Clean Needle Exchange Program, San Diego, California (0.9 million); Street Outreach Services, Seattle, Washington (0.8 million); Prevention Point Philadelphia, Pennsylvania (0.7 million); HIV Education and Prevention Project of Alameda, Oakland, California (0.6 million); Needle Exchange Emergency Distribution, Berkeley, California (0.5 million); and one SEP that wanted program information kept confidential.

⁶⁷⁶ Rapid Assessment of Influenza Vaccination Coverage Among HMO Members — Northern California Influenza Seasons, 2001–02 Through 2004–05

The *MMWR* series of publications is published by the Coordinating Center for Health Information and Service, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, GA 30333.

SUGGESTED CITATION

Centers for Disease Control and Prevention. [Article Title]. MMWR 2005;54:[inclusive page numbers].

Centers for Disease Control and Prevention

Julie L. Gerberding, MD, MPH Director

Dixie E. Snider, MD, MPH Chief Science Officer

Tanja Popovic, MD, PhD (Acting) Associate Director for Science

Coordinating Center for Health Information and Service

Blake Caldwell, MD, MPH, and Edward J. Sondik, PhD (Acting) Directors

National Center for Health Marketing*

Steven L. Solomon, MD (Acting) Director

Division of Scientific Communications*

Maria S. Parker (*Acting*) *Director*

Mary Lou Lindegren, MD (Acting) Editor, MMWR Series

Suzanne M. Hewitt, MPA Managing Editor, MMWR Series

Douglas W. Weatherwax (Acting) Lead Technical Writer-Editor

> Stephanie M. Neitzel Jude C. Rutledge *Writers-Editors*

Lynda G. Cupell Malbea A. LaPete *Visual Information Specialists*

Quang M. Doan, MBA Erica R. Shaver Information Technology Specialists

Notifiable Disease Morbidity and 122 Cities Mortality Data

Patsy A. Hall Deborah A. Adams Felicia J. Connor Rosaline Dhara Donna Edwards Tambra McGee Pearl C. Sharp

* Proposed.

TABLE 1. Number of syringes exchange	ged in syringe exchange
programs (SEPs), by program size -	

SEP size	No. of syringes per SEP	No. of SEPs	Total no. of syringes exchanged	% of total syringes exchanged
Small	<10,000	22	103,266	0.4
Medium	10,000-55,000	35	899,973	3.6
Large	55,001-499,999	51	11,578,468	47.0
Very large	≥500,000	11	12,296,326	49.0
Total		119*	24,878,033	100.0

* Seven of 126 programs responding to the survey did not track the number of syringes exchanged in 2002.

treatment; 91 (72%) offered voluntary on-site counseling and testing for HIV, 54 (43%) for hepatitis C, and 37 (29%) for hepatitis B; 42 (33%) provided vaccination for hepatitis A and 45 (36%) for hepatitis B; 39 (31%) offered sexually transmitted disease (STD) screening; 29 (23%) provided on-site medical care; and 28 (22%) provided tuberculosis screening. Most programs provided risk-reduction and risk-elimination education to IDUs. One hundred fifteen (91%) programs provided education on hepatitis A, B, and C; 114 (90%) on HIV/AIDS prevention; 111 (88%) on safer injection practices; 104 (83%) on abscess prevention and care; 100 (79%) on vein care; 110 (87%) on STD prevention; 110 (87%) on male condom use; and 94 (75%) on female condom use.

During 2002, a total of 126 SEPs maintained an average of six exchange sites each (median: 3.0; range: 1-47). SEPs served clients for an average of 26 hours/week (median: 18 hours/ week; range: 1-202 hours/week). Buildings (e.g., storefronts, clinics, or health centers) were the most commonly reported sites; 68 total SEPs (54%) operated 156 sites/week for 1,334 hours/week). Forty-five (36%) programs served clients through health vans or car stops (203 sites/week for 616.5 hours/week), and 25 (20%) operated other types of fixed sites, such as at tables on streets, in private homes, or at shooting galleries (i.e., locations where persons inject drugs) (141 sites/week for 413.5 hours/week). Fifteen (12%) programs used mobile workers on foot or bicycle (81 sites/week for 202.0 hours/ week). Of the 126 total SEPs in 2002, 69 (55%) had multiple types of exchange sites, 36 (29%) were entirely building-based, 14 (11%) were vehicle-based, five (4%) used other fixed sites, and two (2%) used mobile sites only. Delivery of syringes and other risk-reduction supplies to residences or meeting spots was reported by 62 (49%) SEPs. Secondary exchange (i.e., exchange of syringes on behalf of other persons) was allowed by 103 (82%) programs.

One hundred ten of the 126 SEPs reported 2002 budget information. The reported budgets totaled \$13.0 million. Individual fixed budgets ranged from \$0 (nine SEPs) to \$1,035,831 (mean: \$118,273; median: \$53,500) (Table 2). Thirty-one (28%) operated with budgets of less than \$25,000,

TABLE 2. Characteristics of synnige exchange prog		Office Offi	(0, 100 + 100)		2002	
Characteristic	1994–1995	1996	1997	1998	2000*	2002
No. of SEPs known to NASEN [†]	68	101	113	131	154	148
No. of SEPs participating in survey	60	87	100	110	127	126
No. of cities with SEPs participating in survey	46	71	80	81	106	102
No. of states/territories with SEPs participating in survey	21	29	32	33	35	32
No. of syringes exchanged (millions)	8.0	13.9	17.5	19.4	22.6	24.9
Total SEP budgets (millions)	\$6.2	\$6.5	\$8.4	\$8.6	\$12.1	\$13.0
Total public funding (millions)	\$2.3	\$4.5	\$4.2	\$6.0	\$8.9	\$7.3

TABLE 2. Characteristics of syringe exchange programs (SEPs) — United States, 1994–1998 and 2000–2002

* Previously unpublished data from survey on year 2000 activities, Beth Israel Medical Center, New York City.

[†]North American Syringe Exchange Network.

41 (37%) with budgets of \$25,000-\$100,000, and 38 (35%) with budgets exceeding \$100,000. SEPs reported multiple sources of financial support in 2002, including individual contributors, foundations, and state and local governments. In 2002, 58 (46%) of the 126 programs located in 15 states received public funding totaling approximately \$7.3 million from city, county, and state governments.**

In 2002, for the first time in 8 years, the number of SEPs, the number of localities with SEPs, and the amount of public funding for SEPs in the United States decreased; however, the total number of syringes exchanged and total budgets for all SEPs surveyed continued to increase. During 2000-2002, the number of SEPs known to NASEN decreased 3.8% (from 154 to 148), the number of states/territories with SEPs decreased 8.6% (from 35 to 32), and public funding of SEPs decreased 18% (from \$8.9 million to \$7.3 million). During the same period, the number of syringes exchanged increased 10.2% (from 22.6 million to 24.9 million) and total SEP budgets from public and private funds increased 7.4% (from \$12.1 to \$13.0 million). In addition, compared with data from 1998 (5), the proportion of SEPs in 2002 considered mediumsized (10,000-55,000 syringes exchanged) or large (55,001-499,000 syringes exchanged) increased 19%, whereas the proportion of small SEPs (<10,000 syringes exchanged) decreased 33%.

Reported by: CA McKnight, MPH, DC Des Jarlais, PhD, T Perlis, PhD, K Eigo, Baron Edmond de Rothschild Chemical Dependency Institute, Beth Israel Medical Center, New York; M Krim, PhD, J Auerbach, PhD, American Foundation for AIDS Research, New York, New York. D Purchase, A Solberg, North American Syringe Exchange Network, Tacoma, Washington. TS Jones, RS Garfein, Div of HIV/AIDS Prevention, National Center for HIV, STD, and TB Prevention, CDC. **Editorial Note:** The results of the 2002 survey suggest that although some SEPs became more efficient at obtaining private funding to distribute more syringes, others were unable to maintain operations. As of June 2004, a total of 184 SEPS were known to NASEN, operating in 36 states, DC, Puerto Rico, and Indian Lands (D Purchase, NASEN, personal communication, 2004), indicating that trends might be changing and require additional monitoring.

The findings in this report are subject to at least three limitations. First, the extent of SEP activity in the United States is probably underestimated because 22 (15%) SEPs known to NASEN did not participate in the survey, and others might exist but not be known to NASEN. Second, data collected were based on program director self-reports and were not verified independently. Third, because 26 (21%) SEPs requested that their survey data be kept confidential, some data are presented only as aggregate state-level or program-size information.

Injections of illicit drugs have been estimated to represent approximately one-third of the estimated 2-3 billion injections occurring outside of health-care settings in the United States each year, second only to insulin injections by persons with diabetes (6). Improperly discarded syringes pose a serious risk for injury and infection to sanitation workers and the community (7). SEPs contribute to safe disposal of potentially infectious syringes used by IDUs by removing used syringes from the community, not only through direct exchange but also through supplemental collection programs. For example, in San Francisco in 2000, approximately 2 million syringes were recovered at SEPs, and an estimated 1.5 million syringes were collected through a pharmacy-based program that provided freeof-charge sharps containers and accepted filled containers for disposal. As a result, an estimated 3.5 million syringes were recovered from community syringe users and safely disposed of as infectious waste (8). Other SEPs offer methods for safe disposal of syringes after hours. For example, in Santa Cruz, California, the Santa Cruz Needle Exchange Program, in collaboration with the Santa Cruz Parks and Recreation Department, installed 12 steel sharps containers in public restrooms throughout the county (S Miller, Santa Cruz Needle Exchange Program, personal communication, 2004).

^{***} Public funding from state governments: California, Colorado, Connecticut, Hawaii, Illinois, Massachusetts, New Mexico, New York, Oregon, Rhode Island, Vermont, and Washington. Public funding from county governments: Clark, Cowlitz, King, Skagit, Snohomish, Spokane, Tacoma, and Thurston, Washington; Alameda, Santa Clara, and Santa Cruz, California; Dane and Milwaukee, Wisconsin; Boulder, Colorado; Cook, Illinois; and Multnomah, Oregon. Public funding from city governments: Berkeley, Los Angeles, Reseda, San Francisco, and Santa Monica, California; Coupeville and Seattle, Washington; Chicago, Illinois; Milwaukee, Wisconsin; Portland, Oregon; New York, New York; and Philadelphia, Pennsylvania.

SEPs provide health and social services to IDUs who might not otherwise be reached. They also remove syringes that are potentially contaminated with HIV and other bloodborne infections from the community. Continued monitoring of SEPs in the United States is necessary to evaluate the longterm effects of this public health intervention.

References

- Normand J, Vlahov D, Moses LE, eds. Preventing HIV transmission: the role of sterile needles and bleach. Washington, DC: National Academies Press; 1995. Available at http://www.nap.edu/books/0309052963/ html.
- CDC. Syringe exchange programs—United States, 1994–1995. MMWR 1995;44:684–91.
- 3. CDC. Update: syringe exchange programs—United States, 1996. MMWR 1997;46:565-8.
- CDC. Update: syringe exchange programs—United States, 1997. MMWR 1998;47:652–5.
- CDC. Update: syringe exchange programs—United States, 1998. MMWR 2001;50:384–7.
- 6. American Association of Diabetes Educators, American Diabetes Association, American Medical Association, American Pharmaceutical Association, Association of State and Territorial Health Officials, National Alliance of State and Territorial AIDS Directors. Safe community disposal of needles and other sharps. Houston, TX: Coalition for Safe Community Needle Disposal; 2002. Available at http://www.safeneedledisposal.org/CalltoActionltrASTHOfinal.pdf.
- US Environmental Protection Agency. Protecting your community from sharps: options for safe disposal of sharps. Washington, DC: US Environmental Protection Agency; 2004. Available at http://www.epa.gov/ epaoswer/other/medical/med-govt.pdf.
- Drda B, Gomez J, Conroy R, Seid M, Michaels J. San Francisco Safe Needle Disposal Program, 1991–2001. J Am Pharm Assoc 2002;42 (Suppl 2):S115–6. Available at http://www.aphanet.org/JAPhA/ suppl2_cdc.pdf.

Rapid Assessment of Influenza Vaccination Coverage Among HMO Members — Northern California Influenza Seasons, 2001–02 Through 2004–05

The Vaccine Safety Datalink (VSD) is a collaborative project involving CDC and eight health maintenance organizations* (HMOs) in the United States. Computerized data on vaccination, medical outcomes, and patient demographics are collected and linked under a standard protocol at multiple HMOs (1). Beginning with the 2003–04 influenza season, the VSD team and one of the HMOs, Kaiser Permanente Northern California (KPNC), established an automated system for rapid detection of potentially adverse events after vaccinations among its members. During the 2004-05 influenza season, in response to the influenza vaccine shortfall and resulting prioritization of vaccine distribution (2), this rapid analysis system also was used to assess influenza vaccination coverage weekly among KPNC members. The results indicated that KPNC followed Advisory Committee on Immunization Practices (ACIP) prioritization guidelines by targeting influenza vaccination to children aged 6-23 months and adults aged \geq 65 years. For the 2005–06 influenza season, the rapid analysis system should be expanded to include data from additional HMOs and more detailed information on vaccinees (e.g., high risk for influenza complications [3]) to better characterize influenza vaccination coverage during the 2005-06 influenza season on a weekly basis.


During the 2004–05 influenza season, KPNC had an enrolled population of approximately 3.4 million and received approximately 50% of the influenza vaccine doses it had ordered. By using the KPNC rapid analysis system, the VSD team prospectively assessed weekly influenza vaccination coverage in five age groups (6–23 months, 2–17 years, 18–49 years, 50–64 years, and \geq 65 years) for the 2004–05 influenza season. Beginning in October 2004, KPNC provided weekly counts of influenza vaccinations, stratified by age group, from its immunization registry, which tracks 98.7% of KPNC vaccinations. These data were transmitted to CDC via a secure system. By analyzing estimates of weekly KPNC enrollments and exact vaccination counts, VSD was able to provide weekly estimates of influenza vaccination coverage among the five KPNC age groups.

For influenza seasons before 2004-05, the VSD team obtained monthly estimates of total KPNC enrollment for each age group from existing VSD annual data and retrospectively estimated weekly vaccination coverage among KPNC enrollees. However, for the weekly analysis of 2004-05 data, current enrollment estimates by age group were not available; therefore, monthly KPNC enrollment figures from 2003 were used as a proxy for 2004-05 enrollment. A previous sensitivity analysis of this technique for the 2002-03 influenza season determined that estimates of vaccination coverage differed by a range of 0.5% to 3.1% by week and age group when using 2001–02 enrollment as a proxy for the 2002–03 enrollment. To be counted as enrolled for a given month, a person had to be enrolled for the entire month; age for each enrollee was measured from the start of each month of interest. Monthly enrollment estimates were then used to impute corresponding weekly enrollment numbers.

^{*} Group Health Cooperative (Seattle, Washington); Harvard Pilgrim Health Care, Harvard Medical, and Harvard Vanguard (Boston, Massachusetts); Health Partners Research Foundation (Minneapolis, Minnesota); Kaiser Permanente Colorado (Denver); Kaiser Permanente Northern California (Oakland); Kaiser Permanente Northwest (Portland, Oregon); Marshfield Clinic Research Foundation (Marshfield, Wisconsin); and UCLA Center for Vaccine Research/ Southern California Kaiser Permanente Health Care Plan (Los Angeles).


Among KPNC members, influenza vaccination coverage levels for the 2004–05 influenza season were 57.4% (95% confidence interval [CI] = 56.9%–57.8%) for children aged 6–23 months (Figure 1), 6.6% (CI = 6.6%–6.7%) for children aged 2–17 years, 6.0% (CI = 5.9%–6.1%) for adults aged 18–49 years, 24.1% (CI = 24.0%–24.2%) for adults aged 50–64 years (Figure 2), and 71.8% (CI = 71.6%–71.9%) for adults aged ≥ 65 years (Figure 3). Among two priority groups for influenza vaccination during the 2004–05 influenza season, coverage for children aged 6–23 months was 21.4% greater than the final estimate (47.3%) for the 2003–04 season (Figure 1), and coverage for adults aged ≥ 65 years was similar


FIGURE 1. Cumulative estimated percentage of HMO-enrolled* children aged 6–23 months receiving influenza vaccination, by week — Vaccine Safety Datalink data from Kaiser Permanente Northern California,[†] influenza seasons 2001–02 through 2004–05



* Health maintenance organization.


¹Total enrolled population of 3.4 million (including all ages) in northern California during the 2004–05 influenza season.





^{*} Health maintenance organization.

¹Total enrolled population of 3.4 million (including all ages) in northern California during the 2004–05 influenza season. FIGURE 3. Cumulative estimated percentage of HMO-enrolled* adults aged ≥65 years receiving influenza vaccination, by week — Vaccine Safety Datalink data from Kaiser Permanente Northern California,[†] influenza seasons 2001–02 through 2004–05



* Health maintenance organization.

^TTotal enrolled population of 3.4 million (including all ages) in northern California during the 2004–05 influenza season.

to that for the 2003–04 season (71.7%) (Figure 3). For the remaining age groups, including adults aged 50–64 years (Figure 2), coverage estimates were all significantly less than (p<0.05) final coverage estimates for the previous two influenza seasons.

Reported by: N Lewis, S Black, MD, Kaiser Permanente Northern California, Oakland, California. E Weintraub, MPH, J Baggs, PhD, W Thompson, PhD, F DeStefano, MD, R Davis, MD, Immunization Safety Office; D Shay, MD, National Center for Infectious Diseases, CDC.

Editorial Note: During the 2004–05 influenza season, when vaccine supply was limited, KPNC influenza-vaccination outreach and communication programs for members were targeted to groups at high risk for influenza complications, in accordance with ACIP recommendations (2, 4). As measured by KPNC's new rapid analysis system, vaccination coverage among its members was greater than or similar to that of previous seasons for the two priority age groups, children aged 6–23 months and adults aged ≥65 years. Vaccination coverage for the nonpriority age groups was significantly lower than that for previous years. These results indicate that KPNC was successful in distributing vaccine to the two priority age groups. In addition, for the first time, a system updated weekly was used to estimate vaccination coverage in a large population of persons of all ages. These weekly reports were reviewed by KPNC to monitor compliance with ACIP guidelines.

The cumulative KPNC results for the 2004–05 influenza season approximated those calculated nationally by the telephone-interview–based Behavioral Risk Factor Surveillance System (BRFSS) survey (5), although the two systems differ substantially. The KPNC estimates of vaccination coverage were calculated by using vaccinations recorded in the KPNC immunization registry and estimates of monthly enrollment of members in the northern California HMO. BRFSS estimates were based on the self-reported vaccinations of participating members of the civilian, noninstitutionalized population, regardless of health-insurance status, in all 50 states and the District of Columbia. In addition, the KPNC data include influenza vaccinations through April 2, 2005, whereas the BRFSS data include vaccinations through January 31, 2005.

For adults aged \geq 65 years, KPNC estimated coverage of 71.8%, and BRFSS estimated coverage of 62.7% (CI = 60.6%–64.8%). For adults aged 18–49 years, the estimates were 6.0% for KPNC and 6.9% (CI = 5.9%–7.9%) for BRFSS, and for adults aged 50–64 years, the estimates were 24.1% for KPNC and 16.5% (CI = 14.7%–18.3%) for BRFSS. Among children aged 6–23 months, KPNC estimated coverage of 57.4%, and BRFSS estimated coverage of 48.4% (CI = 39.6%–57.2%). Finally, for children aged 2–17 years, the estimates were 6.6% for KPNC and 12.3% (CI = 10.5%–14.1%) for BRFSS. According to both KPNC and BRFSS data, vaccine uptake was greatest in October and November and tapered off in December and January during the 2004–05 influenza season.

The findings in this report are subject to at least four limitations. First, influenza vaccination coverage in an HMO might not be generalizable to the overall U.S. population. Second, estimates were obtained only from northern California; future assessments are expected to include additional HMOs in other regions. Third, enrollment figures from 2003 were used as a proxy for 2004–05 enrollment. Finally, certain KPNC members might have obtained influenza vaccinations outside of the HMO, resulting in an underestimate of vaccination coverage; however, such vaccination is unlikely because of the limited supply of influenza vaccine during the 2004–05 influenza season.

Rapid analysis enabled weekly estimates of vaccination coverage in a KNPC population of 3.4 million. If expanded to all eight participating HMOs in the VSD, weekly vaccination coverage estimates could be provided for approximately 5.9 million HMO members (1.8% of the U.S. population). Unlike interview-based survey systems, the VSD vaccination data described in this report were not self-reported; they were collected from immunization registry data and therefore were not subject to recall bias. During the 2005-06 influenza season, the VSD rapid analysis system will perform its principal task of gathering data on potentially adverse events after vaccinations (e.g., with the new meningococcal conjugate vaccine [6]). However, the system also will be enhanced by additional HMO populations, and data on influenza vaccinees will enable weekly estimation of vaccination coverage among HMO members at high risk for influenza complications (3).

References


- Chen RT, DeStefano F, Davis RL, et al. The Vaccine Safety Datalink: immunization research in health maintenance organizations in the USA. Bull World Health Organ 2000;78:186–94.
- 2. CDC. Interim influenza vaccination recommendations, 2004–05 influenza season. MMWR 2004;53:923–4.
- 3. CDC. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2005;54(in press).
- 4. CDC. Revised interim guidance for late-season influenza vaccination: January 27, 2005. Atlanta, GA: US Department of Health and Human Services, CDC; 2005. Available at http://www.cdc.gov/flu/protect/pdf/ fluvaccine-lateseasonguidance.pdf.
- CDC. Estimated influenza vaccination coverage among adults and children—United States, September 1, 2004–January 31, 2005. MMWR 2005;54:304–7.
- CDC. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2005;54(No. RR-7).

West Nile Virus Activity — United States, 2005

This report summarizes West Nile virus (WNV) surveillance data reported to CDC through ArboNET as of 3 a.m., Mountain Daylight Time, July 12, 2005.

Eleven states have reported 25 cases of human WNV illness (Figure and Table) in 2005. Nineteen (79%) of the 24 cases for which such data were available occurred in males; the median age of patients was 45 years (range: 17–80 years). Date of illness onset ranged from May 14 to June 30; one case was fatal.

FIGURE. Areas reporting West Nile virus (WNV) activity — United States, 2005*



* As of 3 a.m., Mountain Daylight Time, July 12, 2005.

TABLE. Number of human cases of West Nile virus (WNV) illness, by state — United States, 2005*

State	Neuroinvasive disease [†]	West Nile fever [§]	Other clinical/ unspecified ¹	Total reported to CDC**	Deaths
Arizona	2	1	0	3	0
California	1	1	0	2	0
Colorado	0	7	0	7	0
Georgia	0	0	1	1	0
Indiana	1	0	0	1	0
Kansas	0	1	0	1	0
Missouri	1	0	0	1	1
New Mexico	1	1	0	2	0
Ohio	1	0	0	1	0
South Dakota	a 1	4	0	5	0
Texas	1	0	0	1	0
Total	9	15	1	25	1

* As of 3 a.m., Mountain Daylight Time, July 12, 2005.

⁺ Cases with neurologic manifestations (i.e., West Nile meningitis, West Nile encephalitis, and West Nile myelitis).

§ Cases with no evidence of neuroinvasion.

[¶] Illnesses for which sufficient clinical information was not provided.

** Total number of human cases of WNV illness reported to ArboNet by state and local health departments.

Seven presumptive West Nile viremic blood donors (PVDs) have been reported to ArboNET in 2005. Of these, five were reported in Texas, and two in Arizona.

In addition, 281 dead corvids and 96 other dead birds with WNV infection have been reported from 16 states during 2005. WNV infections have been reported in horses in 11 states. WNV seroconversions have been reported in 40 sentinel chicken flocks in five states (Arizona, Arkansas, California, Florida, and Minnesota). A total of 439 WNV-positive mosquito pools have been reported in 13 states.

Additional information about national WNV activity is available from CDC at http://www.cdc.gov/ncidod/dvbid/ westnile/index.htm and at http://westnilemaps.usgs.gov.

Notice to Readers

2005 Annual Conference on Assessment Initiative — September 20–22, 2005

The 2005 Annual Conference on Assessment Initiative will be held September 20–22, 2005, in Seattle, Washington. The purpose of this meeting is to discuss and share information on innovative systems and methods that improve the way data are used to inform public health programs, services, and policy at the state and local levels. Sessions will cover data dissemination, applied data analysis and presentation techniques, and community health assessment processes and outcomes. The conference is cosponsored by CDC and the National Association for Public Health Statistics and Information Systems.


Participants include staff from state and local health departments, federal agencies, and community organizations involved or interested in the collection, analysis, and dissemination of data for community health assessment. Conference attendees can register online at http://www.psava.com/cha2005. No registration fee will be charged. The deadline for online registration is September 9, 2005. The deadline for making hotel reservations with the Renaissance Seattle Hotel is August 29, 2005 (telephone, 800-546-9184 or 206-583-0300). Additional information for this conference is available at http://www.cdc.gov/epo/dphsi/ai/conference_training.htm.

Notice to Readers

Webcast on Human Papilloma Virus (HPV)

CDC will present a webcast, "HPV and Cervical Cancer: An Update on Prevention Strategies," on August 9, 2005, 1:00-2:00 p.m. EDT. Genital HPV infection is one of the most common sexually transmitted diseases. New information is available about the natural history of HPV infection, the association of different HPV types with various clinical manifestations, HPV transmission, and methods of HPV prevention. In addition, the Food and Drug Administration recently approved the use of a commercially available HPV DNA test for two purposes: 1) management of patients with abnormal Pap test results and 2) as an adjunct to the Pap test for cervical cancer screening in women aged ≥ 30 years. This new information about HPV might require changes in approaches to cervical cancer screening in primary-care practices and in counseling and educating patients and their sex partners. The webcast will address cervical cancer screening guidelines and strategies for preventing genital HPV infection, including appropriate patient counseling messages.

Information about content, registration, continuing education credit, and accessing the webcast is available at http://www. phppo.cdc.gov/phtn/hpv-05. Information about registration is also available from CDC, telephone 800-418-7246 or 404-639-1292.



hospital units of institutions (e.g., prison hospitals), and hospitals with fewer than six beds staffed for patient use are excluded. [†] Categories with ≥1 million hospital discharges. *International Classification of Diseases, Ninth Revision, Clinical Modification* (ICD-9-CM). ICD-9-CM codes for psychoses 290–299; malignant neoplasm 140–208, 230–234; pneumonia 480–486; fractures 800–829; heart disease 391–392.0, 393–398, 402, 404, 410–416, 420–429; and delivery V27.

In 2003, patients in six diagnostic categories had ≥ 1 million hospital discharges. The categories were heart disease (4.4 million), delivery (4.0 million), psychoses (1.6 million), pneumonia (1.4 million), malignant neoplasms (1.3 million), and fractures (1.1 million). The average length of hospital stay for patients with these diagnoses ranged from 2.6 days for deliveries to 8.0 days for psychoses.

SOURCE: DeFrances CJ, Hall MJ, Podgornik MN. 2003 National Hospital Discharge Survey. Advance data from Vital and Health Statistics; no. 359. Hyattsville, MD: US Department of Health and Human Services, CDC, National Center for Health Statistics; 2005. Available at http://www.cdc.gov/nchs/data/ad/ad359.pdf.




FIGURE I. Selected notifiable disease reports, United States, comparison of provisional 4-week totals July 9, 2005, with historical data

* Ratio of current 4-week total to mean of 15 4-week totals (from previous, comparable, and subsequent 4-week periods for the past 5 years). The point where the hatched area begins is based on the mean and two standard deviations of these 4-week totals.

TABLE I. Summary of provisional cases of selected notifiable diseases	United States, cumulative, week ending July 9, 2005 (27th Week)*

Disease	Cum. 2005	Cum. 2004	Disease	Cum. 2005	Cum. 2004
Anthrax	_	_	Hemolytic uremic syndrome, postdiarrheal [†]	68	62
Botulism:			HIV infection, pediatric ⁺¹	150	206
foodborne	5	6	Influenza-associated pediatric mortality**	40	l —
infant	27	41	Measles	49**	19 ^{§§}
other (wound & unspecified)	13	5	Mumps	129	111
Brucellosis	49	49	Plague	2	l —
Chancroid	12	15	Poliomyelitis, paralytic	—	_
Cholera	2	4	Psittacosis [†]	10	7
Cyclosporiasis [†]	592	141	Q fever [†]	50	34
Diphtheria	_	—	Rabies, human	1	_
Domestic arboviral diseases			Rubella	5	9
(neuroinvasive & non-neuroinvasive):		_	Rubella, congenital syndrome	1	_
California serogroup ^{†§}	_	_	SARS [†] **	—	_
eastern equine ^{† §}		_	Smallpox [†]	_	l —
Powassan ^{†§}		_	Staphylococcus aureus:		
St. Louis†§		_	Vancomycin-intermediate (VISA) [†]	_	l —
western equine ^{†§}		_	Vancomycin-resistant (VRSA) [†]	_	1
Ehrlichiosis:		_	Streptococcal toxic-shock syndrome [†]	81	89
human granulocytic (HGE)†	103	111	Tetanus	13	9
human monocytic (HME) [†]	69	86	Toxic-shock syndrome	52	46
human, other and unspecified t	18	12	Trichinellosis	8	_
Hansen disease [†]	37	51	Tularemia [†]	43	40
Hantavirus pulmonary syndrome [†]	8	11	Yellow fever	_	_

-: No reported cases.

* Incidence data for reporting years 2004 and 2005 are provisional and cumulative (year-to-date).

Not notifiable in all states. Ş

Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Infectious Diseases (ArboNet Surveillance).

¹ Updated monthly from reports to the Division of HIV/AIDS Prevention, National Center for HIV, STD, and TB Prevention. Last update May 29, 2005.

*** Updated weekly from reports to the Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases. ††

Of 49 cases reported, 40 were indigenous and nine were imported from another country.

Of 19 cases reported, seven were indigenous and 12 were imported from another country.

^{¶¶} Formerly Trichinosis.

(27th Week)*	AIDS		Chia	mydia [†]	Coccidioir	domycosis	Cryptosp	oridiosis
	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.
Reporting area	2005§	2004	2005	2004	2005	2004	2005	2004
UNITED STATES	16,504	20,011	456,607	470,354	2,228	2,721	992	1,306
NEW ENGLAND	673	729	16,076	15,554			59	75
Maine N.H.	8 10	14 26	1,091 882	1,008 856	<u>N</u>	<u>N</u>	8 7	13 16
Vt. ¹	4	13	517	591	_	_	14	7
Mass.	331	234	7,403	6,858	_	_	21	28
R.I.	68	70	1,673	1,716			1	2
Conn.	252	372	4,510	4,525	N	Ν	8	9
MID. ATLANTIC	3,059 318	4,442 603	54,603 11,290	58,190	N	N	135 36	209 45
Upstate N.Y. N.Y. City	1,725	2,328	18,826	11,427 17,985	IN		30	45 63
N.J.	472	786	5,526	9,262	Ν	Ν	8	17
Pa.	544	725	18,961	19,516	N	N	60	84
E.N. CENTRAL	1,387	1,702	70,929	83,012	4	5	212	346
Ohio Ind.	209 198	229 215	19,366 10,139	21,066	N N	N N	75 11	75 37
III.	664	846	21,195	9,297 23,751			18	55
Mich.	246	323	12,247	19,327	4	5	31	64
Wis.	70	89	7,982	9,571	N	N	77	115
W.N. CENTRAL	394	392	27,122	28,620	3	5	148	167
Minn. Iowa	104 48	92 26	4,233 3,345	6,044 3,376	3 N	N N	42 27	59 30
Mo.	163	169	11,460	10,454		3	55	24
N. Dak.	5	13	546	975	Ν	Ň		8
S. Dak.	9	6	1,408	1,256	—	_	12	22
Nebr.¹ Kans.	18 47	21 65	2,778 3,352	2,731 3,784	N	2 N	1 11	12 12
						_		
S. ATLANTIC Del.	5,315 81	6,029 80	87,586 1,671	87,846 1,472	N	N	208	220
Md.	637	686	9,319	9,695	_	_	12	10
D.C.	407	355	1,934	1,844	_	_	2	4
Va. [¶] W. Va.	273 30	330 30	10,550 1,350	11,071 1,446	N	N	14 4	24 3
N.C.	399	334	17,159	14,603	N	N	25	38
S.C. ¹	287	375	10,314	9,121	_	—	8	11
Ga. Fla.	896 2,305	888 2,951	13,225 22,064	16,724 21,870	N	N	46 97	67 63
					IN			
E.S. CENTRAL Ky.	896 118	946 106	32,912 5,024	30,272 2,868	N	3 N	28 10	51 16
Tenn. ¹	369	386	11,253	11,640	N	N	6	14
Ala. ¹	244	228	6,429	7,056	—	_	11	11
Miss.	165	226	10,206	8,708		3	1	10
W.S. CENTRAL Ark.	1,896 71	2,515 125	57,218 4,472	60,287	—	2 1	26 1	51 10
La.	370	563	9,954	4,216 13,175	_	1	3	10
Okla.	113	87	5,484	5,925	Ν	Ň	14	13
Tex. ¹	1,342	1,740	37,308	36,971	N	N	8	28
MOUNTAIN	643	717	27,283	26,621	1,491	1,652	61	59
Mont. Idaho ¹	4 7	4 11	1,071 1,112	1,306 1,486	N N	N N	11 4	11 6
Wyo.	1	6	568	542	2		2	2
Colo.	127	135	7,161	6,892	N	N	20	25
N. Mex.	60 258	106 278	2,338	4,466 7,565	3 1,453	14 1,596	2 7	3 9
Ariz. Utah	33	31	9,614 2,119	1,780	2	1,590	7	2
Nev. ¹	153	146	3,300	2,584	31	34	8	1
PACIFIC	2,241	2,539	82,878	79,952	730	1,054	115	128
Wash.	196	213	9,949	9,105	N	N	6	
Oreg. ¹ Calif.	117 1,865	131 2,135	4,397 64,136	4,241 61,714	730	1,054	20 89	18 108
Alaska	1,805	2,135	1,970	1,980				_
Hawaii	53	46	2,426	2,912	_	_	_	2
Guam	1	1	_	679	_	_	_	_
P.R.	335	208	2,089	1,956	N	N	N	Ν
V.I. Amer. Samoa	8 U	6 U	32 U	202 U	 U	U	 U	U
C.N.M.I.	2	Ŭ	_	Ŭ	_	Ŭ	_	Ŭ
N: Not potificable				CNML: Comm				

TABLE II. Provisional cases of selected notifiable diseases, United States, weeks ending July 9, 2005, and July 10, 2004 (27th Week)*

N: Not notifiable. U: Unavailable. —: No reported cases. C.N.M.I.: Commonwealth of Northern Mariana Islands. * Incidence data for reporting years 2004 and 2005 are provisional and cumulative (year-to-date). * Chlamydia refers to genital infections caused by *C. trachomatis.* § Updated monthly from reports to the Division of HIV/AIDS Prevention, National Center for HIV, STD, and TB Prevention. Last update May 29, 2005. © Contains data reported through National Electronic Disease Surveillance System (NEDSS).

682

		Escher	<i>ichia coli</i> , Ente	rohemorrhagio	(EHEC)					
		Shiga toxin positive,				n positive,				
	015 Cum.	7:H7 Cum.	serogroup non-O157 Cum. Cum.		not serogrouped Cum. Cum.		Giardi Cum.	asis Cum.	Gonorrhea Cum. Cum.	
Reporting area	2005	2004	2005	2004	2005	2004	2005	2004	2005	2004
UNITED STATES	707	847	97	129	79	67	7,422	8,357	152,905	163,046
NEW ENGLAND	56	57	26	30	10	7	678	765	3,072	3,645
Maine N.H.	9 5	2 10	5 1	5	_	_	83 35	69 19	68 76	130 61
Vt.	6	6	1	_	_	_	74	66	28	45
Mass.	19	27	6	9	10	7	282	347	1,406	1,557
R.I. Conn.	2 15	5 7	13	1 15	_	_	53 151	54 210	257 1,237	469 1,383
MID. ATLANTIC	89	112	7	18	8	16	1,414	1,822	15,571	18,563
Upstate N.Y.	43	43	6	7	3	6	505	568	3,152	3,713
N.Y. City N.J.	3 14	25 18	_	4	_	5	367 171	551 238	4,876 2,066	5,768 3,502
Pa.	29	26	1	7	5	5	371	465	5,477	5,580
E.N. CENTRAL	132	178	8	23	5	8	1,152	1,261	28,219	34,223
Ohio Ind.	44 21	43 19	1	4	3	7	316 N	367 N	8,962	10,730
III.	14	36	1	2	_	1	236	405	3,996 8,558	3,197 10,131
Mich.	29	35	_	4	2	_	333	292	4,632	7,778
Wis.	24	45	6	13		_	267	197	2,071	2,387
W.N. CENTRAL Minn.	102 14	156 32	19 6	19 7	10 2	14 2	866 423	910 307	8,606 1,170	8,464 1,498
lowa	28	46	_	—	_	—	107	124	709	598
Mo.	30	23	8	10	3	4	178	256	4,663	4,324
N. Dak. S. Dak.	1 6	5 11	2	_	_	5	3 37	15 32	31 197	65 136
Nebr.	8	24	3	2	3	_	44	64	678	552
Kans.	15	15	—	—	2	3	74	112	1,158	1,291
S. ATLANTIC Del.	88	70 2	14 N	13 N	35 N	10 N	1,079 18	1,326 26	36,940 408	39,091 472
Md.	16	17	2	2		2	74	49	3,489	4,119
D.C.		1	_	_	_	—	22	38	1,049	1,275
Va. W. Va.	10 1	8 1	6	6	8	_	232 16	183 15	3,652 371	4,403 433
N.C.	_	_		—	19	6	N	N	8,101	7,837
S.C. Ga.	1 13	6 15	2	3	_	_	42 241	48 425	4,346 5,821	4,449 7,157
Fla.	47	20	4	2	8	2	434	542	9,703	8,946
E.S. CENTRAL	38	47	_	3	5	8	174	183	12,405	13,024
Ky.	9	11	—	1	4	5	N	N	1,598	1,259
Tenn. Ala.	16 11	16 12	_	_	1	3	87 87	95 88	3,993 3,696	4,209 4,116
Miss.	2	8	_	2	—	_	_		3,118	3,440
W.S. CENTRAL	24	44	3	2	3	4	113	132	22,706	22,676
Ark. La.	4 3	8 2	3	_	2	_	38 18	55 23	2,324 5,288	2,128 6,003
Okla.	10	9	_	_	—	_	57	54	2,243	2,455
Tex.	7	25	—	2	1	4	N	N	12,851	12,090
MOUNTAIN	69	77 4	18	20	3	_	567	626	5,633	5,519
Mont. Idaho	5 9	4 21	5	3	1	_	20 42	19 81	56 45	49 42
Wyo.	—	1	2	1		_	12	11	30	28
Colo. N. Mex.	15 2	20 6	1 3	1 3	1	_	214 21	211 38	1,438 404	1,582 532
Ariz.	19	7	N	Ν	Ν	Ν	74	88	2,062	1,850
Utah Nev.	10 9	9 9	7	11 1	1	_	148 36	128 50	339	261
PACIFIC					I	_		1,332	1,259 19,753	1,175 17,841
Wash.	109 25	106 35	2	1	_	_	1,379 126	1,332	1,824	1,374
Oreg.	32	12	2	1	—	—	129	198	767	554
Calif. Alaska	43 6	55 1	_	_	_	_	1,052 37	914 33	16,444 268	14,894 324
Hawaii	3	3	—	—	—	—	35	44	450	695
Guam	Ν	Ν	_	_	—	_		2	_	114
P.R. V.I.	_	_	_	_	_	_	26	101	198 2	147 64
Amer. Samoa	U	U	U	U	U	U	U	U	Ű	U
C.N.M.I.	_	U	_	U	_	U		U	_	U

 TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending July 9, 2005, and July 10, 2004

 (27th Week)*

		Haemophilus influenzae, invasive								
	All a					5 years				
	All sero			type b		rotype b	Unknown			
Reporting area	Cum. 2005	Cum. 2004	Cum. 2005	Cum. 2004	Cum. 2005	Cum. 2004	Cum. 2005	Cum. 2004		
UNITED STATES	1,202	1,158	3	8	63	64	119	108		
NEW ENGLAND	93	111	_	1	7	7	4	1		
Maine	5	7	_	—	_	_	1	_		
N.H.	4	13	_	—	—	2	_	_		
Vt. Mass.	6 42	5 55	_	1	2	2	2 1	1		
R.I.	7	3	_		2	_	_	_		
Conn.	29	28	—	—	3	3	—	—		
MID. ATLANTIC	239	238	_	1	_	3	29	28		
Upstate N.Y.	69	81	—	1	—	3	5	4		
N.Y. City N.J.	43 44	50 42	_		_	_	9 7	9 2		
Pa.	83	65	_	_	_	_	8	13		
E.N. CENTRAL	157	217	1	_	1	8	10	31		
Ohio	81	67	_	—	_	2	7	10		
Ind.	41	33	—	—	1	4	1	1		
III. Mich.	15 13	71 14	1		_	2	2	16 3		
Wis.	7	32	_	_	_		_	1		
W.N. CENTRAL	63	61	_	2	3	3	9	5		
Minn.	21	27	_	1	3	3	_	_		
lowa	_	1	—	1	—	—	_	_		
Mo. N. Dak.	30 1	22 3	_	_	_	_	7 1	4		
S. Dak.	_		_	_	_	_	_	_		
Nebr.	6	2	—	_	_	_	1	_		
Kans.	5	6	—	—	—	_	—	1		
S. ATLANTIC	283	263	1	_	17	18	15	18		
Del. Md.	40	46	_	_	4	5	_	—		
D.C.	40	2	_	_			_	1		
Va.	26	23	—	_	_			1		
W. Va. N.C.	16 52	10 37	1	_	1	3	3	1		
S.C.	13	7	_	_	5	5	1	1		
Ga.	57	74	—	_	_	_	7	14		
Fla.	79	64	—	_	7	5	4	—		
E.S. CENTRAL	71	43		—	1	—	12	7		
Ky. Tenn.	6 49	3	—	—	1	_	1 7			
Ala.	16	29 11	_	_	_	_	4	5 2		
Miss.	_	_	_	—	—	_	_	_		
W.S. CENTRAL	71	47	1	1	5	5	6	1		
Ark.	4	1		_	1	_	_	_		
La. Okla.	26 41	9 36	1	_	2 2	5	6	1		
Tex.		1	_	1	<u> </u>		_	_		
MOUNTAIN	165	125	_	3	16	15	27	12		
Mont.	_	_	_	_	_			_		
Idaho	3	5	—	_	_	_	1	2		
Wyo. Colo.	3 30	30	_	_	_	_	1 6	3		
N. Mex.	15	26	_	_	4	5	1	4		
Ariz.	89	44	—		10	6	9	1		
Utah Nev.	12 13	9 11	—	2 1	2	1 3	7 2	1		
			—	1				-		
PACIFIC Wash.	60	53 1	_		13	5	7	5 1		
Oreg.	24	26	_	_	_	_	5	2		
Calif.	26	17	—	—	13	5	1	1		
Alaska	4	5	—	_	—	_	1	1		
Hawaii	6	4	—			—	_			
Guam P.R.	_	1	_	_	_	_	_	1		
V.I.	_	_	_	_	_	_	_	_		
Amer. Samoa	U	U	U	U	U	U	U	U		
C.N.M.I.		U		U	_	U	_	U		

TABLE II. (*Continued*) Provisional cases of selected notifiable diseases, United States, weeks ending July 9, 2005, and July 10, 2004 (27th Week)*

684

Vol. 54 / No. 27	
------------------	--

(27th Week)*		Hepatitis (viral, acute), by type								
		Α		B		C				
Reporting area	Cum. 2005	Cum. 2004	Cum. 2005	Cum. 2004	Cum. 2005	Cum. 2004				
UNITED STATES	1,858	2,975	2,845	2,992	412	364				
NEW ENGLAND Maine	255 1	441 8	156 8	192 1		7				
N.H.	46	11	10	22	_	_				
Vt. Mass.	3 174	8 373	2 113	2 95		1 6				
R.I.	5	10	1	3	U	—				
Conn. MID. ATLANTIC	26 304	31 369	22 585	69 392	53	 66				
Upstate N.Y.	53	42	49	38	12	3				
N.Y. City N.J.	154 47	144 85	55 371	77 107	_	_				
Pa.	50	98	110	170	41	63				
E.N. CENTRAL	180	236	194	275	65	45				
Ohio Ind.	27 22	27 24	71 15	66 16	1 15	3 3				
III. Mich.	38 77	77 84	19 89	33 135	49	12 27				
Wis.	16	24		25	49	<u> </u>				
W.N. CENTRAL	56	87	189	182	25	6				
Minn. Iowa	3 15	23 28	11 65	20 11	3	4				
Mo. N. Dak.	27	16 1	83	118 3	20	2				
S. Dak.		2		—	1	_				
Nebr. Kans.	3 8	9 8	14 16	17 13	1	_				
S. ATLANTIC	275	532	742	965	149	90				
Del.	1	5	34	25	78	4				
Md. D.C.	28 2	68 4	89 4	84 13	18	2 1				
Va. W.Va.	43 3	45 1	84 20	108 4	8 5	8 16				
N.C.	39	34	86	92	9	6				
S.C. Ga.	10 49	32 198	53 95	78 287	2 4	8 7				
Fla.	100	145	277	274	25	38				
E.S. CENTRAL Ky.	117 6	90 12	188 36	247 27	46 4	38 16				
Tenn.	84	64	69	119	8	10				
Ala. Miss.	14 13	6 8	44 39	40 61	8 26	2 10				
W.S. CENTRAL	107	399	193	153	18	57				
Ark. La.	4 36	51 21	20 27	63 30	8	1 3				
Okla.	3	17	20	39	_	2				
Tex.	64	310	126	21	10	51				
MOUNTAIN Mont.	183 7	233 4	291 3	231 1	20	21 2				
Idaho Wyo.	15	11 3	6 1	6 7	—	1				
Colo.	21	22	27	23	10	4				
N. Mex. Ariz.	9 111	12 149	7 198	10 120	_	U 3				
Utah	13	25	29	22	6	2				
Nev. PACIFIC	7 381	7	20 307	42	4	9 34				
Wash.	23	588 32	37	355 28	29 7	9				
Oreg. Calif.	26 319	41 498	47 213	61 254	11 11	10 14				
Alaska	3	3	7	8	—	—				
Hawaii	10	14	3	4	—	1				
Guam P.R.	— 14	1 23	9	10 42		8				
V.I. Amer. Samoa	U	U	U	U	U	U				
C.N.M.I.	<u> </u>	Ŭ	_	Ŭ	_	U				

TABLE II. (*Continued*) Provisional cases of selected notifiable diseases, United States, weeks ending July 9, 2005, and July 10, 2004 (27th Week)*

(27th Week)*	Legio	nellosis	Liete	eriosis	Lyme	Lyme disease		Malaria	
	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.	
Reporting area	2005	2004	2005	2004	2005	2004	2005	2004	
UNITED STATES	610	795	259	301	3,785	6,996	513	662	
NEW ENGLAND	38	23	9	13	256	1,113	26	58	
Maine N.H.	2 4	_	1	3 1	18 31	29 49	3 3	4	
Vt.	_	1	_	_	5	16	1	3	
Mass. R.I.	23 3	14 2	5 1	4 1	131 3	720 76	17 2	36 2	
Conn.	6	6	2	4	68	223	<u> </u>	13	
MID. ATLANTIC	173	184	60	67	2,616	4,576	141	164	
Upstate N.Y. N.Y. City	44 19	36 23	22 10	20 11	628	1,280 148	25 65	19 81	
N.J.	34	24	9	17	945	1,410	31	37	
Pa.	76	101	19	19	1,043	1,738	20	27	
E.N. CENTRAL	120	190	24	55	49	552	40	62 15	
Ohio Ind.	57 8	89 16	11 1	17 10	31 6	22 4	12	7	
III.	12	24	_	11	_	54	11	18	
Mich. Wis.	32 11	53 8	7 5	15 2	4 8	5 467	13 4	13 9	
W.N. CENTRAL	19	20	11	5	149	80	26	41	
Minn.	1	1	2	1	112	39	11	18	
lowa	3 9	3	4	1	23	13	4	2	
Mo. N. Dak.	1	11 1	2 2	_2	12	20	10	11 2	
S. Dak.	2	1	_	<u> </u>	_	_	_	1	
Nebr. Kans.	1 2	1 2	1	1	2	6 2	1	2 5	
S. ATLANTIC	140	170	61	39	621	598	106	153	
Del.	8	3	N	N	222	88	—	3	
Md. D.C.	35 2	32 7	10	6	298 3	387 2	37 3	30 8	
Va.	12	16	5	6	40	34	11	12	
W.Va.	5	3	2	1	3	2	1	—	
N.C. S.C.	14 3	15 6	11 1	8 1	24 7	49 6	15 3	9 7	
Ga.	11	25	11	8	—	10	16	33	
Fla.	50	63	21	9	24	20	20	51	
E.S. CENTRAL Ky.	26 7	42 11	12 1	17 4	16 1	23 11	12 3	20 1	
Tenn.	10	19	6	8	15	9	6	4	
Ala. Miss.	8 1	11 1	4 1	3 2	_	3	3	11 4	
W.S. CENTRAL	10	91	12	23	31	15	33	68	
Ark.	1	—		2	2	2	2	6	
La. Okla.	4 2	5 2	6	2	3	2	2 2	4	
Tex.	3	84	6	19	26	11	27	56	
MOUNTAIN	52	43	5	12	3	5	27	22	
Mont.	4 1	1 5	—	1	1	2	—	1	
ldaho Wyo.	1 3	5 4	_	I 		2	1		
Colo.	15	8	2	3	_	_	15	7	
N. Mex. Ariz.	2 14	1 10	1	_	_	1	5	1 5	
Utah	6	11		1	2	<u> </u>	4	5	
Nev.	7	3	2	7	_		2	3	
PACIFIC Wash.	32	32 5	65 6	70 6	44 1	34 2	102 8	74 3	
Oreg.	Ν	N	4	5	5	14	3	10	
Calif. Alaska	32	27	55	57	37 1	18	83 3	58	
Hawaii	_	_	_	2	I N	N	5	3	
Guam	_	_	_	_	_	_	_	_	
P.R.	—	_	—	_	N	Ν	1	—	
V.I. Amer. Samoa	U	U	U	U	U	U	U	 U	
C.N.M.I.	_	U	—	U	—	U	_	U	

TABLE II. (*Continued*) Provisional cases of selected notifiable diseases, United States, weeks ending July 9, 2005, and July 10, 2004 (27th Week)*

	Meningococcal disease													
	All sero	aroupe	Seroo A, C, Y, a		Serogr	oup B	Other se	rogroup	Seregrou	ounknown				
_	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.				
Reporting area	2005 700	2004 744	2005 53	2004 60	2005 36	2004 30	2005	2004 1	2005 611	2004 653				
NEW ENGLAND	52	41	1	5		5	_	1	51	30				
Maine	2	8	_		_	1	_	_	2	7				
N.H.	8	3	_	—	—	—	—	_	8	3				
Vt. Mass.	4 26	1 24	_	5	_	4	_	_	4 26	1 15				
R.I.	2	1	_	_	_	—	_	_	2	1				
Conn.	10	4	1	—	—	—	—	1	9	3				
MID. ATLANTIC	92	111	27	33	4	5	—	—	61	73				
Upstate N.Y. N.Y. City	23 12	32 20	3	5	3	3	_	_	17 12	24 20				
N.J.	26	20		_	_	_	_	_	26	20				
Pa.	31	39	24	28	1	2	—	_	6	9				
E.N. CENTRAL	61	78	15	15	5	5	—	_	41	58				
Ohio Ind.	28 10	41 12	_	3	5	4 1	_	_	23 10	34 11				
III.	3	1	_	_	_		_	_	3	1				
Mich.	15	12	15	12	—	—	—	_	_					
Wis.	5	12		_		_	—	_	5	12				
W.N. CENTRAL Minn.	44 6	48 14	2 1	_	1	4	_	_	41 5	44 14				
lowa	12	10	_	_	1	2	_	_	11	8				
Mo.	15	14	1	_	—	1	_	—	14	13				
N. Dak. S. Dak.	2	1 2	_	_	_	1	_	_	2	1				
Nebr.	3	2	_	_	_	_	_	_	3	2				
Kans.	6	5	_	—	—	—	—	_	6	5				
S. ATLANTIC	136	146	4	2	7	2	—	_	125	142				
Del.	2	2 7	2	—		—	—	_	2 11	2 7				
Md. D.C.	15	5		2	2	_	_	_		3				
Va.	16	10	_	_	—	—	—	_	16	10				
W. Va. N.C.	5 20	4 23	1 1	—	5	2	_	_	4 14	4 21				
S.C.	12	13	_	_	5		_	_	14	13				
Ga.	12	9	—	—	_	—	_	—	12	9				
Fla.	54	73	_	—	—	—	—	—	54	73				
E.S. CENTRAL	35	36	—	1	3	—	—	—	32	35				
Ky. Tenn.	11 15	5 11	_	1	3	_	_	_	8 15	4 11				
Ala.	5	10	_	_	_	_	_	_	5	10				
Miss.	4	10	_	—	—	_	—	_	4	10				
W.S. CENTRAL	55	42	1	1	5	1	—	—	49	40				
Ark. La.	9 24	10 25	_	1	2	_	_	_	9 22	10 24				
Okla.	12	4	1		3	1	_	_	8	3				
Tex.	10	3	—	—	—	—	—	_	10	3				
MOUNTAIN	59	41	2	1	5	4	_	_	52	36				
Mont. Idaho	1	3 4	_	_	_	_	_	_	1	3 4				
Wyo.	—	3	_	_	_	_	_	_	_	3				
Colo.	13	11	2	_	—	_	—	—	11	11				
N. Mex. Ariz.	1 32	6 6	_	1	2	3	_	_	1 30	2 6				
Utah	7	3	_	_	2	_	_	_	5	3				
Nev.	5	5	—	—	1	1	—	_	4	4				
PACIFIC	166	201	1	2	6	4	—	—	159	195				
Wash. Oreg.	30 25	17 40	1	2	4	4		_	25 25	11 40				
Calif.	101	137	_	_	_	_	_	_	101	137				
Alaska	1	2	_	—	_	—	—	—	1	2				
Hawaii	9	5	—	_	2	_	—	_	7	5				
Guam P.R.	4	9	—	—	—	—	—	—	4					
V.I.	4	9	_	_	_	_	_	_	4	9				
Amer. Samoa	—	—	—	—	—	—	—	—	—	—				
C.N.M.I.	_	—	_	_	_	_	_	_	_	_				

TABLE II. (*Continued*) Provisional cases of selected notifiable diseases, United States, weeks ending July 9, 2005, and July 10, 2004 (27th Week)*

	Pertu	issis	Rabies,	animal		lountain d fever	Salmoi	nellosis	Shigellosis		
Reporting area	Cum. 2005	Cum. 2004	Cum. 2005	Cum. 2004	Cum. 2005	Cum. 2004	Cum. 2005	Cum. 2004	Cum. 2005	Cum. 2004	
UNITED STATES	8,608	6,467	2,572	3,158	428	472	14,546	16,371	5,102	6,213	
NEW ENGLAND Maine N.H.	513 13 25	818 4 25	364 27 7	269 30 10	1 N	9 N	963 74 78	833 39 48	118 4 4	126 2 5	
/t. Mass. R.I.	59 384 12	40 708 16	27 214 8	10 108 18	— — 1	8 1	49 522 40	25 516 48	6 71 9	2 80 8	
Conn. MID. ATLANTIC Jpstate N.Y. N.Y. City	20 727 264 44	25 1,219 885 82	81 288 229 16	93 414 210 9	28 1 2		200 1,833 509 405	157 2,229 468 624	24 528 145 204	29 655 294 191	
N.J. Pa.	126 293	88 164	N 43	N 195	8 17	8 16	260 659	447 690	140 39	114 56	
E.N. CENTRAL Ohio Ind. III. Mich. Wis.	1,771 663 146 206 114 642	1,834 225 45 380 64 1,120	62 30 4 17 11	33 9 4 11 7 2	15 12 1 2 —	17 6 4 6 1	1,932 562 147 486 384 353	2,300 537 214 761 392 396	358 39 33 84 128 74	478 80 93 190 54 61	
W.N. CENTRAL Minn. Iowa Mo. N. Dak. S. Dak. Nebr. Kans.	1,221 337 344 223 67 1 114 135	414 76 45 202 52 11 5 23	202 37 36 31 13 38 	324 25 38 15 36 68 69 73	62 1 58 - 2 - 1	51 1 43 — 7	1,031 254 152 330 15 63 75 142	1,089 266 216 292 19 50 70 176	546 31 42 393 2 16 31 31	183 24 38 78 2 7 7 27	
S. ATLANTIC Del. Md. D.C. Va. W. Va. N.C. S.C. Ga. Fla.	544 13 98 4 91 28 41 163 18 88	324 60 6 87 5 46 53 15 52	860 141 290 22 264 5 135 3	1,238 9 148 233 33 346 87 177 205	217 1 23 9 3 146 10 15 10	214 3 19 7 1 110 24 41 9	3,795 32 282 20 371 66 605 204 568 1,647	3,668 30 301 18 373 72 388 312 722 722 1,452	906 5 29 8 46 88 40 229 461	1,505 3 55 21 138 293 361 576 361 39 172 120 30	
E.S. CENTRAL Ky. Tenn. Ala. Miss.	246 71 115 40 20	75 11 41 13 10	76 7 24 45	71 13 23 28 7	56 — 44 11 1	66 — 35 17 14	885 145 280 270 190	1,008 151 286 257 314	699 115 379 161 44		
W.S. CENTRAL Ark. La. Okla. Tex.	251 135 22 — 94	323 21 10 17 275	543 20 54 469	641 28 73 540	21 12 3 5	65 34 3 27 1	1,000 301 300 170 229	1,710 215 356 150 989	877 32 56 393 396	1,769 31 189 259 1,290	
MOUNTAIN Mont. Idaho Wyo. Colo. N. Mex. Ariz. Utah Nev.	2,131 401 66 19 738 70 597 213 27	551 15 18 3 281 80 107 37 10	108 	66 10 	23 1 1 3 — 13 4 —	9 2 1 2 1 2 1 2	945 41 54 25 237 78 304 136 70	1,033 67 79 23 257 111 310 104 82	313 5 2 46 36 180 19 25	380 4 6 1 65 68 196 19 21	
PACIFIC Wash. Oreg. Calif. Alaska Hawaii	1,204 275 369 478 22 60	909 329 248 312 10 10	69 2 66 1	102 2 89 11	5 - 5 -	4 2 2	2,162 213 154 1,636 24 135	2,501 221 213 1,845 32 190	757 38 35 664 6 14	756 54 36 637 5 24	
Guam P.R. V.I.	1		 32 	 30	N	N		44 190	1	34 13	
Amer. Samoa C.N.M.I.		U U		U U	U 	U U wealth of North	U 	U U	<u> </u>	U U	

 TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending July 9, 2005, and July 10, 2004

 (27th Week)*

(27th Week)*											
	Chrombooo		coccus pneum	oniae, invasi	ve disease	Syphilis					
		cal disease, e, group A	Drug res all a		Age <	5 years	Primary & s		Congenital		
Reporting area	Cum. 2005	Cum. 2004	Cum. 2005	Cum. 2004	Cum. 2005	Cum. 2004	Cum. 2005	Cum. 2004	Cum. 2005	Cum. 2004	
UNITED STATES	2,530	2,844	1,363	1,365	477	465	3,863	3,919	119	215	
NEW ENGLAND	96	198	22	80	50	67	113	106		1	
Maine	6	6	N	N	—	2	1	2	—	_	
N.H. Vt.	8 9	15 8	9	6	3 3	N 1	6	3	_	_	
Mass.	66	90	_	22	44	39	81	63	_	—	
R.I. Conn.	7	17 62	13 U	7 45	U	5 20	2 23	15 23	_	1	
MID. ATLANTIC	581	497	137	103	94	70	483	507	10	23	
Upstate N.Y. N.Y. City	188 100	161 77	53 U	46 U	44 17	46 U	39 312	42 305	4 5	1 9	
N.J.	116	108	N	N	14	6	63	90	1	12	
Pa.	177	151	84	57	19	18	69	70	—	1	
E.N. CENTRAL Ohio	505 125	662 159	362 236	318 228	124 54	114 56	374 109	468 123	20 2	28 1	
Ind.	52 110	73	118	90	31	22 1	36	31	1 6	1 4	
III. Mich.	196	184 192	8	N	35	N	178 40	188 106	9	4 22	
Wis.	22	54	N	N	4	35	11	20	2	—	
W.N. CENTRAL Minn.	164 60	197 96	32	13	52 29	50 31	123 31	96 17	1	3 1	
Iowa	N	N	N	N	_	N	1	4	_	_	
Mo. N. Dak.	47 5	42 9	27	10	5 2	8 2	76	54	1	1	
S. Dak.	16	8	3	3	—	_	_		_	_	
Nebr. Kans.	12 24	14 28	2 N	N	6 10	5 4	3 12	5 16	_	1	
S. ATLANTIC	518	556	555	698	56	34	968	945	24	37	
Del. Md.	1 124	3 86	1	4	 36	N 22	6 175	3 174	8	1 5	
D.C.	6	5	14	5	2	4	62	31	_	1	
Va. W.Va.	44 12	42 16	N 76	N 75	 18	N 8	65 2	53 3	3	1	
N.C.	80	84	N	N	U	U	119	85	7	4	
S.C. Ga.	20 89	46 140	109	77 168	_	N N	30 136	65 158	1	10 2	
Fla.	142	134	355	369	—	Ν	373	373	5	13	
E.S. CENTRAL Ky.	110 23	150 47	118 21	94 21	5 N	9 N	217 17	211 24	13	15 1	
Tenn.	87	103	97	71	_	N	98	74	9	7	
Ala. Miss.	_	_	_	2	5	N 9	84 18	90 23	3 1	5 2	
W.S. CENTRAL	103	221	89	43	57	93	655	615	33	42	
Ark.	10	9	12	6	13	7	29	23	_	3	
La. Okla.	6 73	2 44	77 N	37 N	19 16	21 28	138 22	145 18	5 1	3 2	
Tex.	14	166	N	N	9	37	466	429	27	34	
MOUNTAIN Mont.	398	313	48	15	33	28	197 5	206 1	14	27	
Idaho	1	5	Ν	N	—	N	18	13	1	2	
Wyo. Colo.	2 149	6 62	20 N	5 N	32	28	21	1 38	_	_	
N. Mex.	25	69	_	N	_	_	27	53	1	2	
Ariz. Utah	170 50	146 24	N 27	N 8	1	<u>N</u>	69 4	85 4	12	23	
Nev.	1	1	1	2	—	_	53	11	—	_	
PACIFIC Wash.	55 N	50 N	N	1 N	6 N	N	733 64	765 52	4	39	
Oreg.	N	N	N	N	5	N	16	18	_	_	
Calif. Alaska		_	<u>N</u>	<u>N</u>	N	N N	646 4	692	4	39	
Hawaii	55	50	_	1	1	_	3	3	_	_	
Guam					—			1			
P.R. V.I.	N	N	N	N	_	N	102	73 4	6	3	
Amer. Samoa C.N.M.I.	U	U U	U	U U	U	U U	U	U U	U	U U	
		0									

TABLE II. (*Continued*) Provisional cases of selected notifiable diseases, United States, weeks ending July 9, 2005, and July 10, 2004 (27th Week)*

					Vari	icella	West Nile virus disease [†]				
		rculosis	Typhoi			enpox)	1	nvasive	Non-neuroinvasive [§]		
Reporting area	Cum. 2005	Cum. 2004	Cum. 2005	Cum. 2004	Cum. 2005	Cum. 2004	Cum. 2005	Cum. 2004	Cum. 2005		
UNITED STATES	5,028	6,462	102	137	13,281	12,622	26	159	7		
NEW ENGLAND	158	213	12	14	935	1,832	_	_	—		
Maine N.H.	8 4	11 8	1	_	206 159	180	_	_	_		
Vt.	4	_	_		32	406	—	_	_		
Mass. R.I.	105 14	120 25	7 1	12 1	538	56	_	_	_		
Conn.	23	49	3	1	U	1,190	_	_	_		
MID. ATLANTIC	1,014	999	28	35	2,888	60	_	3	_		
Jpstate N.Y. N.Y. City	130 524	124 514	5 8	2 13	_	_	_	2	_		
N.J.	221	214	8	11		60	_	1	_		
Pa.	139	147	7	9	2,888				_		
E.N. CENTRAL Ohio	670 134	576 105	5	16 3	3,863 878	3,979 999	2 1	1	_		
nd.	64 324	69	1	8	120	N	1	_	_		
III. Mich.	108	251 111	2	8 4	25 2,585	1 2,497	_	1	_		
Nis.	40	40	2	1	255	482	—	—	—		
W.N. CENTRAL	215	234 84	2 2	3	205	130	7	4	4		
Vinn. Iowa	88 17	19			N	N	_	2	_		
Mo. N. Dak.	59	69 3	_	1	131	2	1	1	_		
S. Dak.	2 6	5	_	_	10 64	73 55	5	_	3		
Nebr. Kans.	14 29	16 38	_	_	_	_	1	1	1		
S. ATLANTIC	1,048	1,310	13	17	1,120	1,515	1	4	-		
Del.	2	14	—	_	14	4	_	-	_		
/d. D.C.	119 28	128 4	3	5	18	 18	_	_	_		
/a.	134	104	3	3	209	353	_	_	_		
V. Va. I.C.	12 108	12 139	2	3	643	848 N	_	_	N		
S.C.	106	108	_	—	236	292	_	_	_		
Ga. Fla.	164 375	330 471	2 3	3 3	_	_	1	4	_		
E.S. CENTRAL	286	294	1	6	_	_	1	3	_		
<у.	56	54	1	2	Ν	Ν	_	_	_		
Tenn. Ala.	132 98	108 99	_	4	_	_	1	2	_		
Viss.		33	_	_	_	_	—	1	—		
N.S. CENTRAL	430	1,073	3	10	2,625	3,608	1	5	_		
Ark. _a.	49	63	_	_	103	46	_	1	_		
Okla.	71	80	_	_	_	_	_		—		
Tex.	310	930	3	10	2,522	3,562	1	4	_		
MOUNTAIN Mont.	166 6	268 4	3	6	1,645	1,498	12	118	2		
daho	—		—	_		_	—	—	—		
Nyo. Colo.	27	1 69	_	1	43 1,169	22 1,181	7	4	_		
N. Mex.	8	19	_	_	101	U	2	—	1		
Ariz. Jtah	112 13	108 22	1	2 1	332	295	3	113	1		
Nev.	—	45	1	2			—	1	_		
PACIFIC	1,041	1,495	35	30			2	21	1		
Vash. Dreg.	109 54	121 41	2 2	2	<u>N</u>	<u>N</u>	_	_	_		
Calif.	802	1,257	25	22	_	_	2	21	1		
Alaska Hawaii	15 61	16 60	6	6	_	_	_	_	_		
Guam	_	36	_	_	_	86	_	_	_		
P.R.	—	49	—	—	106	255	_	_	—		
V.I. Amer. Samoa	U	U	 U	U	U	 U	U	U	_		
C.N.M.I.	_	Ŭ	-	Ŭ	_	Ŭ	-	Ŭ			

 TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending July 9, 2005, and July 10, 2004

 (27th Week)*

N: Not notifiable. U: Unavailable. —: No reported cases. C.N.M.I.: Commonwealth of Northern Mariana Islands. * Incidence data for reporting years 2004 and 2005 are provisional and cumulative (year-to-date). † Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Infectious Diseases (ArboNet Surveillance). * Not previously notifiable.

690

TABLE III. Deaths in 122 U.S. cities,* week ending July 9, 2005 (27th Week)

TABLE III. Deaths	in 122 U.			y age (ye		2005 (27th we	ек)	All causes, by age (years)						
D	All		45.04	05.44			P&I [†]	Den time Ann	All		45.04	05.44			P&I [†]
Reporting Area	Ages	<u>≥</u> 65	45-64	25-44	1-24	<1 12	Total	Reporting Area	Ages	<u>≥</u> 65	45-64		1-24	<1	Total
NEW ENGLAND Boston, Mass.	426 112	300 72	82 29	22 3	10 4	12	41 8	S. ATLANTIC Atlanta, Ga.	948 107	563 56	241 34	80 15	31 1	32 1	46 2
Bridgeport, Conn.	32	24	29	1		2	5	Baltimore, Md.	153	86	42	18	5	2	12
Cambridge, Mass.	16	13	1	1	1	_	3	Charlotte, N.C.	125	64	35	9	6	11	8
Fall River, Mass.	18	11	4	1	1	1	2	Jacksonville, Fla.	116	76	22	12	3	3	5
Hartford, Conn.	28	20	4	1	2	1	6	Miami, Fla.	U	U	U	U	U	U	U
Lowell, Mass.	19	12	6		—	1	2	Norfolk, Va.	31	18	4	4	3	2	1
Lynn, Mass.	13	10	1	1	_	1	1	Richmond, Va.	48	29	10	3	3	3	6
New Bedford, Mass. New Haven, Conn.	23	20	1 5	1	1	1	1	Savannah, Ga. St. Petersburg, Fla.	38	27	9	1	1	1	3
Providence, R.I.	23 46	16 32	10	3	_	1	4	Tampa, Fla.	45 172	32 118	11 35	8	5	5	8
Somerville, Mass.	3	1	1	1	_	_	_	Washington, D.C.	102	52	35	7	4	4	_
Springfield, Mass.	34	22	6	5	1	_	2	Wilmington, Del.	11	5	4	2	_	_	1
Waterbury, Conn.	12	9	2	1	_	_	2	E.S. CENTRAL	717	465	160	54	20	18	58
Worcester, Mass.	47	38	7	2	—	—	4	Birmingham, Ala.	142	405	34	54 9	20	7	13
MID. ATLANTIC	1,917	1,336	400	119	38	21	81	Chattanooga, Tenn.	66	47	14	3	_	2	5
Albany, N.Y.	44	34	7	2	1	_	2	Knoxville, Tenn.	59	45	5	6	1	2	5
Allentown, Pa.	25	22	1	2	_	_	2	Lexington, Ky.	76	54	11	5	3	3	5
Buffalo, N.Y.	98	75	16	4	1	2	5	Memphis, Tenn.	183	111	53	16	3	_	14
Camden, N.J.	21	15	4	1	—	1	2	Mobile, Ala.	44	28	12	3	—	1	4
Elizabeth, N.J. Erie. Pa.	21 41	20 27	1 10	4	_	_	3 3	Montgomery, Ala. Nashville. Tenn.	24	18 74	4	2 10	9	3	5 7
Jersey City, N.J.	36	18	10	4	1	_			123	74	27				
New York City, N.Y.	896	626	182	56	18	13	31	W.S. CENTRAL	1,127	695	282	84	42	24	49
Newark, N.J.	53	19	21	10	1	_	_	Austin, Tex.	76	51	15	5	3	2	4
Paterson, N.J.	18	9	6	3	_	_	_	Baton Rouge, La.	36 U	25 U	9 U	1 U	1 U	 U	2 U
Philadelphia, Pa.	270	182	65	13	7	3	8	Corpus Christi, Tex. Dallas, Tex.	162	93	40	13	12	4	6
Pittsburgh, Pa.§	44	28	11	4	1	—	2	El Paso, Tex.	40	27	40	4	1	-	2
Reading, Pa.	24	18	3	3	_	_	2	Ft. Worth, Tex.	109	70	21	8	5	5	4
Rochester, N.Y. Schenectady, N.Y.	131 17	93 15	26 2	7	3	2	9 2	Houston, Tex.	293	176	77	22	12	6	17
Scranton, Pa.	26	18	2	1	_	_	2	Little Rock, Ark.	61	39	18	2	—	2	1
Syracuse, N.Y.	99	74	16	5	4	_	6	New Orleans, La.	56	34	13	5	2	2	1
Trenton, N.J.	20	16	4	_	_	_	1	San Antonio, Tex.	165	103	42	12	5	3	6
Utica, N.Y.	16	11	3	1	1	—	_	Shreveport, La. Tulsa, Okla.	28 101	18 59	8 31	2 10	1	_	6
Yonkers, N.Y.	17	16	1	—	—	—	1								
E.N. CENTRAL	1,696	1,089	395	118	49	45	100	MOUNTAIN Albuquerque, N.M.	771 104	498 61	177 26	63 11	19 4	13 2	41 2
Akron, Ohio	43	27	7	4	_	5	3	Boise, Idaho	35	25	6	_	1	3	1
Canton, Ohio Chicago, III.	38 316	30 177	5 90	2 32	10	1 7	3 27	Colo. Springs, Colo.	42	34	4	2	1	1	1
Cincinnati, Ohio	21	15	30	2		1	2	Denver, Colo.	85	39	28	10	6	2	4
Cleveland, Ohio	156	102	28	11	6	9	6	Las Vegas, Nev.	238	153	58	19	6	1	13
Columbus, Ohio	182	117	42	14	6	3	11	Ogden, Utah Phoenix, Ariz.	27 U	21 U	3 U	2 U	 U	1 U	3 U
Dayton, Ohio	83	58	21	2		2	1	Pueblo, Colo.	33	17	11	5	_		1
Detroit, Mich.	150	78	48	13	8	3	8	Salt Lake City, Utah	96	62	23	9	1	1	7
Evansville, Ind. Fort Wayne, Ind.	44 46	35 27	9 14	2	3	_	4	Tucson, Ariz.	111	86	18	5	_	2	9
Gary, Ind.	+0	6	1	1		_	_	PACIFIC	1,392	932	312	85	39	23	105
Grand Rapids, Mich.	41	30	5	2	4	_	2	Berkeley, Calif.	11	9	2	_	_		3
Indianapolis, Ind.	180	118	42	12	3	5	14	Fresno, Calif.	86	57	19	7	3	_	6
Lansing, Mich.	46	31	9	1	3	2	4	Glendale, Calif.	17	12	5	_	_	_	2
Milwaukee, Wis.	83	61	17	4	—	1	6	Honolulu, Hawaii	60	45	10	4	—	1	3
Peoria, III.	35	21	9	3 1	1	2	3	Long Beach, Calif.	47	34	11 72	2	10	4	4 31
Rockford, III. South Bend, Ind.	50 34	37 26	11 6	1	1	_	3	Los Angeles, Calif. Pasadena, Calif.	318 5	210 4	1	19	13	4	1
Toledo. Ohio	100	59	24	9	4	4	1	Portland, Oreg.	83	60	11	4	2	5	5
Youngstown, Ohio	40	34	4	2	_	_	4	Sacramento, Calif.	165	111	36	9	4	5	10
W.N. CENTRAL	594	378	134	48	17	17	32	San Diego, Calif.	129	83	31	7	5	3	5
Des Moines, Iowa	75	53	134	40	1	3	6	San Francisco, Calif.	86	55	18	6	5	2	7
Duluth, Minn.	48	34	9	2	2	1	2	San Jose, Calif.	104	76	20	3	4	1	14
Kansas City, Kans.	21	11	7	1	2	_	_	Santa Cruz, Calif.	23	15	7	1	_	_	1
Kansas City, Mo.	47	29	10	5	2	1	2	Seattle, Wash. Spokane, Wash.	116	66	35	13	1	1 1	6
Lincoln, Nebr.	27	17	6	3	1	—	3	Tacoma, Wash.	51 91	33 62	12 22	4 6	1		3 4
Minneapolis, Minn.	92	47	27	10	3	5	5	,							
Omaha, Nebr.	71	54	11	4	_	2	6	TOTAL	9,588 [¶]	6,256	2,183	673	265	205	553
St. Louis, Mo.	72	34	21	14	1	2	1								
St. Paul, Minn. Wichita, Kans.	86 55	60 39	16 11	4 3	3 2	3	5 2								
monita, Nano.	55	03		5	2		2	1							

U: Unavailable. —: No reported cases.

* Mortality data in this table are voluntarily reported from 122 cities in the United States, most of which have populations of ≥100,000. A death is reported by the place of its occurrence and by the week that the death certificate was filed. Fetal deaths are not included.

[†] Pneumonia and influenza.

[§] Because of changes in reporting methods in this Pennsylvania city, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks.

¹ Total includes unknown ages.

The Morbidity and Mortality Weekly Report (MMWR) Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format and on a paid subscription basis for paper copy. To receive an electronic copy each week, send an e-mail message to *listserv@listserv.cdc.gov*. The body content should read *SUBscribe mmwr-toc*. Electronic copy also is available from CDC's World-Wide Web server at *http://www.cdc.gov/mmwr* or from CDC's file transfer protocol server at *ftp://ftp.cdc.gov/pub/publications/mmwr*. To subscribe for paper copy, contact Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; telephone 202-512-1800.

Data in the weekly *MMWR* are provisional, based on weekly reports to CDC by state health departments. The reporting week concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the following Friday. Address inquiries about the *MMWR* Series, including material to be considered for publication, to Editor, *MMWR* Series, Mailstop K-95, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30333; telephone 888-232-3228.

All material in the MMWR Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

All MMWR references are available on the Internet at http://www.cdc.gov/mmwr. Use the search function to find specific articles.

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

References to non-CDC sites on the Internet are provided as a service to *MMWR* readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of these sites. URL addresses listed in *MMWR* were current as of the date of publication.

☆U.S. Government Printing Office: 2005-733-116/00099 Region IV ISSN: 0149-2195